Please login to the form below

Not currently logged in
Email:
Password:

urothelial carcinoma

This page shows the latest urothelial carcinoma news and features for those working in and with pharma, biotech and healthcare.

BMS presses go on Nektar combo pivotal trials, despite data debate

BMS presses go on Nektar combo pivotal trials, despite data debate

The phase I/II PIVOT trial met the criteria needed to advance PD-1 inhibitor Opdivo (nivolumab) and CD122-biased agonist NKTR0214 into pivotal trials in melanoma, renal cell carcinoma and ... Nektar and BMS also reported initial stage 1 data in

Latest news

More from news
Approximately 2 fully matching, plus 23 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics